U.S. markets close in 22 minutes
  • S&P 500

    3,667.44
    -25.79 (-0.70%)
     
  • Dow 30

    29,331.24
    -259.17 (-0.88%)
     
  • Nasdaq

    10,849.41
    -18.51 (-0.17%)
     
  • Russell 2000

    1,664.50
    -15.09 (-0.90%)
     
  • Crude Oil

    76.96
    -1.78 (-2.26%)
     
  • Gold

    1,634.70
    -20.90 (-1.26%)
     
  • Silver

    18.43
    -0.48 (-2.54%)
     
  • EUR/USD

    0.9618
    -0.0070 (-0.72%)
     
  • 10-Yr Bond

    3.8780
    +0.1810 (+4.90%)
     
  • GBP/USD

    1.0693
    -0.0163 (-1.50%)
     
  • USD/JPY

    144.6070
    +1.2870 (+0.90%)
     
  • BTC-USD

    19,185.93
    +211.80 (+1.12%)
     
  • CMC Crypto 200

    440.66
    +7.56 (+1.75%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

·1 min read
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc.

IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29, 2022 at 2:00 p.m. ET in New York City.

To register in advance for the fireside chat webcast, sign up here.

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com